Real-World Experience Using Tafasitamab Plus Lenalidomide and/or Loncastuximab Tesirine in a Predominately Hispanic Population with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Latiolais, Heidi [1 ]
Horowitz, Justin [1 ]
Michalek, Joel [2 ]
Duque, Adolfo Enrique Diaz [1 ]
机构：
[1] Univ Texas Hlth San Antonio, MD Anderson Canc Ctr, San Antonio, TX USA
[2] Univ Texas Hlth San Antonio, Dept Populat Hlth Sci, San Antonio, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-207515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7780 / 7781
页数：2
相关论文
共 50 条
  • [1] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [2] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Xu, Bo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) : 707 - 719
  • [3] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Bo Xu
    European Journal of Clinical Pharmacology, 2022, 78 : 707 - 719
  • [4] Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma
    Goparaju, Krishna
    Caimi, Paolo F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) : 1373 - 1381
  • [5] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
    Furqan, Fateeha
    Hamadani, Mehdi
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [6] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
  • [7] Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Nedved, Adrienne
    Maddocks, Kami
    Nowakowski, Grzegorz S.
    ONCOLOGIST, 2023, : 199 - 207
  • [8] RE-MIND: Comparing Tafasitamab plus Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Zinzani, Pier Luigi
    Rodgers, Thomas
    Marino, Dario
    Frezzato, Maurizio
    Barbui, Anna Maria
    Castellino, Claudia
    Meli, Erika
    Fowler, Nathan H.
    Salles, Gilles
    Feinberg, Bruce
    Kurukulasuriya, Nuwan C.
    Tillmanns, Sascha
    Parche, Stephan
    Dey, Debarshi
    Fingerle-Rowson, Gunter
    Ambarkhane, Sumeet
    Winderlich, Mark
    Nowakowski, Grzegorz S.
    CLINICAL CANCER RESEARCH, 2021, 27 (22) : 6124 - 6134
  • [9] Loncastuximab tesirine for diffuse large B-cell lymphoma
    Zurko, J.
    Hamadani, M.
    DRUGS OF TODAY, 2021, 57 (12) : 733 - 743
  • [10] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
12345